56
Participants
Start Date
October 31, 2013
Primary Completion Date
March 31, 2014
Study Completion Date
March 31, 2014
BIIB019 subcutaneous injection
participants will be randomized to receive a single subcutaneous injection of BIIB019, 75 mg or 150 mg per dose group
Research Site, Leeds